[RESEARCH BLOG] · 2026-09-02
Shattuck Labs (STTK) Under Pressure: SELL Signal Amid Crisis Regime
By Pierre Brunelle · Founder & Research Lead
Shattuck Labs, Inc. (NASDAQ: STTK) closed at $6.87, down 2.00 % as of 2026‑09‑01 (Tuesday). The LOPJLB platform has issued a SELL directional signal with a ‑5 score while the broader market regime is flagged as CRISIS.
Shattuck Labs has been the subject of several recent market‑focused stories.
-
Shattuck Labs: A Receptor‑Side Bet On The TL1A Boom highlighted the company’s strategic “receptor‑side bet” on the emerging TL1A therapeutic target, noting that the firm’s experimental compound SL‑172154 is positioned to capitalize on what analysts describe as a “boom” in TL1A‑driven drug pipelines. The piece underscored the high‑risk, high‑reward nature of the bet, given that the drug remains in Phase 1 trials for ovarian, fallopian tube, and peritoneal cancers.
-
What Shattuck Labs Stock Topped the Market on Monday reported that STTK’s stock “topped the market on Monday,” driven largely by a brief surge in trading volume after the company disclosed the pricing of a $75 million public offering. The article pointed out that the capital raise, announced on June 10, was intended to fund continued clinical development and expand the company’s pipeline, but cautioned that dilution risk remains a concern for existing shareholders.
-
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: ? ran a feature labeling Shattuck Labs as a “great momentum stock,” citing a recent uptick in analyst coverage and a series of bullish research notes. The story referenced a consensus price target of $13.20 and highlighted that at least one broker has upgraded the stock to a Buy recommendation, despite the company’s ongoing losses.
-
In a comparative piece, Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison placed Shattuck Labs side‑by‑side with Geron, drawing attention to differences in cash‑burn rates, market‑cap size, and pipeline focus. The analysis noted that while Geron’s assets are more diversified across hematology, STTK’s exposure is concentrated in a single early‑stage oncology candidate, amplifying both upside potential and downside risk.
-
Finally, a Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here’s is How to Trade “trade‑the‑trend” article from mid‑August projected that Wall Street analysts could see STTK rally 85 % from current levels, based on a combination of forward‑looking earnings estimates and a perceived undervaluation relative to peers. The piece, however, warned that the rally assumption hinges on successful Phase 1 read‑outs and a stable macro‑environment—conditions that are far from in the present crisis regime.
Fundamentals and Valuation
Shattuck Labs remains a pre‑profit, clinical‑stage biotechnology firm with a market capitalization of $620.9 million. The company’s valuation metrics reflect its developmental status and ongoing cash consumption:
| Metric | Value |
|---|---|
| P/E (TTM) | ‑13.47 |
| EV/EBITDA | ‑11.56 |
| Gross margin | ‑750.9 % |
| Net margin | ‑5 256.8 % |
| ROE | ‑43.57 % |
| ROA | ‑23.82 % |
All profitability ratios are negative, indicating that STTK is still generating losses at every level of the income statement. The price‑to‑book (P/B) ratio sits at 4.22, suggesting that the market is pricing the firm at more than four times its book value—a premium that may be justified only by expectations of future breakthrough data.
Revenue has been volatile over the past six years. In 2020, the company posted $9.93 million in sales, which rose sharply to $30.02 million in 2021 as the firm expanded its research collaborations. A steep decline to $0.65 million in 2022 reflects the termination of several early‑stage licensing deals and the shift of focus to the SL‑172154 program. Revenue rebounded modestly to $1.66 million in 2023, climbed to $5.72 million in 2024, and fell again to $1.00 million in 2025. The erratic pattern underscores the company’s reliance on milestone payments rather than recurring product sales.
Earnings per share (EPS) have been consistently negative. The 2020 EPS of ‑$0.88 deepened to ‑$1.07 in 2021, then swung to ‑$2.41 in 2022 as cash burn accelerated. The following years saw modest improvement, with EPS of ‑$2.05 in 2023, ‑$1.49 in 2024, and ‑$0.70 in 2025. While the trajectory hints at a narrowing loss per share, the absolute numbers remain far from breakeven.
Free cash flow (FCF) has been persistently negative, ranging from ‑$34.4 million in 2020 to ‑$39.9 million in 2025. The company’s Debt‑to‑Equity (D/E) ratio of 1.27 indicates a moderate leverage level, but given the lack of operating cash generation, any additional debt could exacerbate liquidity concerns.
A discounted cash‑flow (DCF) analysis embedded in the LOPJLB model assigns a 1126.4 % weight to the DCF component, reflecting the heavy reliance on forward‑looking cash‑flow assumptions in a firm that currently has no positive cash‑flow streams. The consensus analyst target price of $13.20 represents a ~92 % upside from the current $6.87 close, but this optimism is predicated on successful Phase 1 outcomes and a subsequent acceleration of the pipeline.
Overall, the valuation picture is one of high uncertainty. The negative earnings multiples, extreme margin compression, and erratic revenue pattern combine to create a risk‑heavy profile that aligns with the SELL signal generated by LOPJLB.
ETF Ownership
STTK is held by a single exchange‑traded fund, CNCR, which accounts for 3.23 % of the company’s outstanding shares and ranks #25 among the fund’s holdings. While a 3 % stake does not constitute a controlling interest, it does represent a modest concentration of institutional ownership that can influence short‑term price dynamics, especially in a thinly traded biotech where trading volume is often driven by a handful of large holders.
| ETF | Weight |
|---|---|
| CNCR | 3.23 % |
Investors monitoring ETF flows should note that any significant rebalancing by CNCR could create additional volatility in STTK’s share price, particularly given the broader market’s crisis‑mode sentiment.
LOPJLB Signal Read
The LOPJLB platform currently flags STTK with a SELL directional signal and a ‑5 score, reflecting a strong bearish bias. The market regime is classified as CRISIS, a three‑day designation that signals heightened systemic risk and reduced risk appetite across equity markets. The composite PERF score of 55.50 and a FUND quality score of 0.00 suggest that the stock’s recent price performance is weak and that fundamental quality metrics are lacking.
The stock’s Value, Growth, GARP, and Quality scores sit at 6.00, 4.00, 3.60, and 5.80 respectively, positioning the ticker in the Balanced archetype. This balanced classification indicates that the stock does not lean strongly toward any single investment style, but rather presents a mixed profile that is difficult to reconcile with the current crisis environment.
Readers are encouraged to explore the interactive chart above on this page for a visual overlay of the signal components, and to review the full stock detail and methodology at the LOPJLB site for deeper insight into how the signal was derived: https://www.lopjlb.com/methodology.
Further Research & Resources
- Detailed stock page: https://www.lopjlb.com/stock/STTK
- Earnings information (if applicable): https://www.lopjlb.com/stock/STTK/earnings.md
- Full‑screen screener for comparable biotech names: https://www.lopjlb.com/screener
The content above is for informational and research purposes only and does not constitute investment advice. All data are sourced from publicly available filings and third‑party news outlets.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.